What is it about?

Hepidemiológicos studies show that antimicrobial combination regimens are more effective against KPC-2-producing bacteria than monotherapy, however, does not define the doses and the mode of administration to the patient. Our study evaluated the pharmacodynamics of combined regimens of meropenem with fosfomycin and confirmed synergism of activities in the combination, as also proposed the doses and the form of administration.

Featured Image

Why is it important?

The current study makes a significant contribution to the understanding of the effective treatment paradigm with combination therapy when compared to monotherapy using pharmacodynamic analysis and proposes a viable alternative for the treatment of serious infections caused by KPC-2 producing Klebsiella pneumoniae infections that affect patients worldwide.

Perspectives

As the antimicrobial action is based on pharmacodynamic principles, our study is one of the first to propose a pharmacodynamic explanation of the best results of combination therapy than monotherapy against KPC-2- producing bacteria, and its results should be confirmed with further studies.

James Albiero

Read the Original

This page is a summary of: Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae, Antimicrobial Agents and Chemotherapy, May 2016, ASM Journals,
DOI: 10.1128/aac.03099-15.
You can read the full text:

Read

Contributors

The following have contributed to this page